| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
8,312 |
7,221 |
$811K |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
4,110 |
3,547 |
$398K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
1,955 |
1,526 |
$236K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
779 |
634 |
$150K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
911 |
712 |
$126K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
714 |
658 |
$107K |
| 36415 |
Collection of venous blood by venipuncture |
9,042 |
5,653 |
$77K |
| 70450 |
Computed tomography, head or brain; without contrast material |
1,197 |
807 |
$74K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
579 |
529 |
$64K |
| 80053 |
Comprehensive metabolic panel |
6,523 |
4,737 |
$41K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
879 |
639 |
$41K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
7,069 |
5,036 |
$25K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
212 |
174 |
$21K |
| 81025 |
|
1,197 |
1,055 |
$19K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
2,768 |
1,952 |
$19K |
| 84484 |
|
2,332 |
1,530 |
$17K |
| 83880 |
|
2,249 |
1,563 |
$16K |
| 94761 |
|
2,717 |
2,052 |
$16K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
1,353 |
1,098 |
$16K |
| 71045 |
Radiologic examination, chest; single view |
2,415 |
1,682 |
$15K |
| 82550 |
|
2,285 |
1,515 |
$15K |
| 83615 |
|
2,226 |
1,490 |
$15K |
| 81001 |
|
3,791 |
2,828 |
$14K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
1,653 |
1,285 |
$13K |
| 85610 |
|
2,057 |
1,216 |
$11K |
| 85730 |
|
1,484 |
1,086 |
$11K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,053 |
1,678 |
$10K |
| 87275 |
|
2,418 |
1,965 |
$9K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
1,088 |
810 |
$8K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
224 |
124 |
$8K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
1,121 |
907 |
$7K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
692 |
516 |
$5K |
| 83690 |
|
841 |
692 |
$4K |
| 71046 |
Radiologic examination, chest; 2 views |
94 |
75 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,659 |
1,401 |
$3K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,248 |
859 |
$2K |
| 84443 |
Thyroid stimulating hormone (TSH) |
945 |
713 |
$2K |
| 80061 |
Lipid panel |
795 |
624 |
$2K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
33 |
30 |
$1K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
491 |
284 |
$747.89 |
| 83036 |
Hemoglobin; glycosylated (A1C) |
464 |
386 |
$721.75 |
| 87040 |
|
26 |
12 |
$531.84 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
25 |
13 |
$484.98 |
| 82330 |
|
36 |
27 |
$460.17 |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
18 |
14 |
$366.29 |
| 82803 |
|
37 |
25 |
$357.76 |
| 83605 |
|
45 |
26 |
$357.76 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
349 |
290 |
$319.99 |
| 86328 |
|
28 |
26 |
$313.55 |
| 82553 |
|
17 |
12 |
$201.14 |
| 84439 |
|
159 |
115 |
$165.40 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
91 |
71 |
$115.33 |
| 87807 |
|
187 |
156 |
$28.65 |
| 87276 |
|
44 |
44 |
$8.84 |
| 82607 |
|
31 |
24 |
$7.16 |
| 81002 |
|
42 |
25 |
$3.41 |
| 83735 |
|
15 |
12 |
$0.00 |
| 96368 |
|
23 |
19 |
$0.00 |
| 82947 |
|
53 |
52 |
$0.00 |